Developing a drug to be administered via the ophthalmic, auricular and nasal routes requires focus on key factors such as drug stabilisation and endotoxin levels. High purity excipients can maximise the success rate of drug development by offering enhanced active pharmaceutical ingredients (API) stability, reduced cellular irritation and minimised endotoxin contribution to the final formulation. They can also add significant benefits to the drug development process, including: optimised drug performance, increased patient compliance, decreased formulation development time and increased speed to market.